FOLFOXIRI in Pregnant Women with Colorectal Cancer: A Case Report and Review of the Literature by Landon Kozai, Kevin Benavente, Adham Obeidat, Jared Acoba

Subjects: Get full text

TRIBE-2: a phase III, randomized, open-label, strategy trial in unresectable metastatic colorectal cancer patients by the GONO group by Chiara Cremolini, Federica Marmorino, Fotios Loupakis, Gianluca Masi, Carlotta Antoniotti, Lisa Salvatore, Marta Schirripa, Luca Boni, Vittorina Zagonel, Sara Lonardi, Giuseppe Aprile, Emiliano Tamburini, Vincenzo Ricci, Monica Ronzoni, Filippo Pietrantonio, Chiara Valsuani, Gianluca Tomasello, Alessandro Passardi, Giacomo Allegrini, Samantha Di Donato, Daniele Santini, Alfredo Falcone, on behalf of all the investigators of the Gruppo Oncologico del Nord Ovest

Subjects: Get full text

Survival benefit of surgical resection after first-line triplet chemotherapy and bevacizumab in patients with initially unresectable metastatic colorectal cancer by Mahmoud A. Elshenawy, Ahmed Badran, Ali Aljubran, Ahmed Alzahrani, M. Shahzad Rauf, Abdelmoneim Eldali, Shouki Bazarbashi

Subjects: Get full text

Ramucirumab plus triplet chemotherapy as an alternative salvage treatment for patients with metastatic colorectal cancer by Yi-Hsin Liang, Jin-Tung Liang, Ben-Ren Lin, John Huang, Ji-Shiang Hung, Shuo-Lun Lai, Tzu-Chun Chen, Jia-Huei Tsai, Yung-Ming Cheng, Ting-Han Tsao, Wen-Ling Hsu, Kuo-Hsing Chen, Kun-Huei Yeh

Subjects: Get full text

FOLFOXIRI versus FOLFOX or FOLFIRI with targeted therapy in patients with mutant BRAF metastatic colorectal cancer: A systematic review and meta-analysis by M. Yu. Fedyanin, E. M. Polyanskaya, H. H.-M. Elsnukaeva, A. A. Tryakin, I. A. Pokataev, A. A. Bulanov, S. A. Tjulandin

Subjects: Get full text

Feasibility and Efficacy of Neoadjuvant Chemotherapy without Radiotherapy for Locally Advanced Rectal Cancer by Katsuji Tokuhara, Yuki Matsui, Yosuke Ueyama, Kazuhiko Yoshioka, Mitsugu Sekimoto

Subjects: Get full text

Primary versus secondary antiemetic prophylaxis with NK1 receptor antagonists in patients affected by gastrointestinal malignancies and treated with a doublet or triplet combinatio... by Alessandro Parisi, Alessandro Parisi, Riccardo Giampieri, Alex Mammarella, Cristiano Felicetti, Lisa Salvatore, Lisa Salvatore, Maria Bensi, Maria Bensi, Maria Grazia Maratta, Maria Grazia Maratta, Antonia Strippoli, Roberto Filippi, Roberto Filippi, Maria Antonietta Satolli, Maria Antonietta Satolli, Angelica Petrillo, Bruno Daniele, Michele De Tursi, Michele De Tursi, Pietro Di Marino, Pietro Di Marino, Guido Giordano, Matteo Landriscina, Pasquale Vitale, Ina Valeria Zurlo, Emanuela Dell’Aquila, Silverio Tomao, Ilaria Depetris, Francesca Romana Di Pietro, Federica Zoratto, Davide Ciardiello, Davide Ciardiello, Maria Vittoria Pensieri, Ornella Garrone, Barbara Galassi, Claudio Ferri, Rossana Berardi, Michele Ghidini

Subjects: Get full text

Protocol of the EFFORT study: a prospective study of FOLFIRI plus aflibercept as second-line treatment after progression on FOLFOXIRI plus bevacizumab or during maintenance treatme... by Hironaga Satake, Koji Ando, Eiji Oki, Mototsugu Shimokawa, Akitaka Makiyama, Hiroshi Saeki, Akihito Tsuji, Masaki Mori

Subjects: Get full text

Treatment with bevacizumab and FOLFOXIRI in patients with advanced colorectal cancer: presentation of two novel trials (CHARTA and PERIMAX) and review of the literature by Stein Alexander, Glockzin Gabriel, Wienke Andreas, Arnold Dirk, Edelmann Thomas, Hildebrandt Bert, Hollerbach Stephan, Illerhaus Gerald, Königsrainer Alfred, Richter Michael, Schlitt Hans J, Schmoll Hans-Joachim

Subjects: “…FOLFOXIRI…”
Get full text

FOLFOXIRI in patients with colon cancer and isolated non-resectable liver metastases: phase II prospective non-randomized single-center study by M. Yu. Fedyanin, E. M. Polyanskaya, I. A. Pokataev, A. A. Tryakin, O. V. Sekhina, D. A. Chekini, Kh.-Kh. M. Elsnukaeva, A. N. Polyakov, I. V. Sagaydak, V. D. Podluzhniy, V. A. Aliev, S. S. Gordeev, D. V. Kuzmichev, Z. Z. Mamedli, S. A. Tjulandin

Subjects: Get full text

Phase II study on first-line treatment of NIVolumab in combination with folfoxiri/bevacizumab in patients with Advanced COloRectal cancer RAS or BRAF mutated – NIVACOR trial (GOIRC... by Angela Damato, Francesco Iachetta, Lorenzo Antonuzzo, Guglielmo Nasti, Francesca Bergamo, Roberto Bordonaro, Evaristo Maiello, Alberto Zaniboni, Giuseppe Tonini, Alessandra Romagnani, Annalisa Berselli, Nicola Normanno, Carmine Pinto

Subjects: Get full text

FOLFOXIRI plus cetuximab as conversion therapy for unresectable RAS/BRAF wild-type left-sided colorectal cancer with liver-limited metastases: a prospective dual-center pilot study by Wenwei Yang, Dong Chen, Yaru Niu, Guifu Wu, Zhangkan Huang, Xinyu Bi, Hong Zhao, Xu Che, Xu Che, Yongkun Sun

Subjects: Get full text

Evaluation of circulating tumor DNA as a prognostic and predictive biomarker in BRAF V600E mutated colorectal cancer—results from the FIRE‐4.5 study by Susanne Klein‐Scory, Alexander Baraniskin, Wolff Schmiegel, Thomas Mika, Roland Schroers, Swantje Held, Kathrin Heinrich, David Tougeron, Dominik P. Modest, Ingo Schwaner, Jan Eucker, Rudolf Pihusch, Martina Stauch, Florian Kaiser, Christoph Kahl, Meinolf Karthaus, Christian Müller, Christof Burkart, Sebastian Stintzing, Volker Heinemann

Subjects: Get full text

Early evaluation of liver metastasis using spectral CT to predict outcome in patients with colorectal cancer treated with FOLFOXIRI and bevacizumab by Shenglin Li, Long Yuan, Mengying Yue, Yuan Xu, Suwei Liu, Feng Wang, Xiaoqin Liu, Fengyan Wang, Juan Deng, Qiu Sun, Xianwang Liu, Caiqiang Xue, Ting Lu, Wenjuan Zhang, Junlin Zhou

Subjects: Get full text

AtezoTRIBE: a randomised phase II study of FOLFOXIRI plus bevacizumab alone or in combination with atezolizumab as initial therapy for patients with unresectable metastatic colorec... by Carlotta Antoniotti, Beatrice Borelli, Daniele Rossini, Filippo Pietrantonio, Federica Morano, Lisa Salvatore, Sara Lonardi, Federica Marmorino, Stefano Tamberi, Salvatore Corallo, Giampaolo Tortora, Francesca Bergamo, Di Stefano Brunella, Alessandra Boccaccino, Elisa Grassi, Patrizia Racca, Emiliano Tamburini, Giuseppe Aprile, Roberto Moretto, Luca Boni, Alfredo Falcone, Chiara Cremolini

Subjects: “…FOLFOXIRI…”
Get full text

Remarkable response to fluorouracil, leucovorin, oxaliplatin, and irinotecan therapy in urothelial cancer of the renal pelvis: a case report by Takuya Tsujino, Kiyoshi Takahara, Tomohisa Matsunaga, Yuki Yoshikawa, Tomoaki Takai, Taizo Uchimoto, Kenkichi Saito, Naoki Tanda, Hajime Hirano, Hayahito Nomi, Naokazu Ibuki, Teruo Inamoto, Haruhito Azuma

Subjects: Get full text

Clinical utility of polyethylene glycol conjugated granulocyte colony-stimulating factor (PEG-G-CSF) for preventing severe neutropenia in metastatic colorectal cancer patients trea... by Yusuke Kitagawa, Hiroki Osumi, Eiji Shinozaki, Yumiko Ota, Izuma Nakayama, Takeshi Suzuki, Takeru Wakatsuki, Mariko Ogura, Akira Ooki, Daisuke Takahari, Mitsukuni Suenaga, Keisho Chin, Kensei Yamaguchi

Subjects: “…FOLFOXIRI plus bevacizumab…”
Get full text

Neoadjuvant chemotherapy with modified FOLFOXIRI for locally advanced rectal cancer to transform effectively EMVI and MRF from positive to negative: results of a long-term single c... by Wen Zhang, Haitao Zhou, Jun Jiang, Yuelu Zhu, Shuangmei Zou, Liming Jiang, Yuan Tang, Jianwei Liang, Yongkun Sun, Zhichao Jiang, Wang Qu, Ying Li, Aiping Zhou

Subjects: Get full text

Recurrence monitoring using ctDNA in patients with metastatic colorectal cancer: COSMOS-CRC-03 and AURORA studies by E. Oki, R. Nakanishi, K. Ando, I. Takemasa, J. Watanabe, N. Matsuhashi, T. Kato, Y. Kagawa, M. Kotaka, K. Hirata, M. Sugiyama, T. Kusumoto, Y. Miyamoto, K. Toyosaki, J. Kishimoto, Y. Kimura, T. Yoshizumi, Y. Nakamura

Subjects: Get full text

Real-world uptake and effectiveness of triplet versus doublet chemotherapy with bevacizumab in patients with metastatic colorectal cancer in the United States by W.J. Chapin, MD, MSCE, W.-T. Hwang, PhD, R. Mamtani, MD, MSCE, M.H. O’Hara, MD

Subjects: “…FOLFOXIRI plus bevacizumab…”
Get full text